Inceptionr LLC Purchases Shares of 8,722 TG Therapeutics, Inc. (NASDAQ:TGTX)

Inceptionr LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 8,722 shares of the biopharmaceutical company's stock, valued at approximately $263,000.

Several other institutional investors have also recently made changes to their positions in the stock. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 1,737 shares during the period. Synergy Asset Management LLC acquired a new position in shares of TG Therapeutics during the 4th quarter worth about $75,000. Finally, GAMMA Investing LLC raised its holdings in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 2,171 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on TGTX shares. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a report on Monday, November 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.67.

Remove Ads

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Stock Performance

NASDAQ TGTX traded down $0.17 on Thursday, reaching $37.06. The stock had a trading volume of 4,299,100 shares, compared to its average volume of 2,619,010. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market cap of $5.82 billion, a P/E ratio of -370.56 and a beta of 2.30. The firm has a fifty day moving average of $31.52 and a two-hundred day moving average of $28.83. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $40.31.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.